A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
Condition: HER2-negative Metastatic Breast Cancer Interventions: Drug: DAN-222; Drug: Niraparib Sponsor: Dantari, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | HER2 | Research | Study